Sida, hépatite C et usage de drogues chez les hommes qui ont des relations sexuelles avec des hommes

Publications

Sida, hépatite C et usage de drogues chez les hommes qui ont des relations sexuelles avec des hommes

10 octobre 2013

Le croisement entre les rapports sexuels non protégés et la consommation de drogues dans la rue et en milieux festifs est susceptible d’exacerber la transmission du sida, de l'hépatite C et des MST chez les hommes ayant des rapports sexuels avec des hommes. Pour en savoir plus, en anglais, veuillez lire les informations ci-dessous.

Abonnez-vous à l'Alerte mensuelle de l'IDPC pour recevoir des informations relatives à la politique des drogues.

The report by Tony Kirby and Michelle Thornber-Dunwell (July 27, p 295)uncovers an emerging and troubling public health and community issue. The intersection of unprotected sex and use of street and party drugs is likely to amplify the transmission of HIV, hepatitis C virus (HCV), and sexually transmitted infections (STI) in men who have sex with men (MSM).

Early diagnosis and treatment is increasingly becoming, or will likely become, the dominant approach to control STIs, HIV, and viral hepatitis. With use of a similar approach for these related infections, it might become more feasible to implement coordinated control strategies that are effective. However, one of the large dangers for which we provide warning is risk disinhibition and primary prevention fatigue, which we are seeing as starting to counteract the benefits of improved access to diagnostic testing and effective treatment. In the longer term, research with vulnerable MSM is needed to better understand the range of relevant factors including how these men perceive risk and balance that against pleasure and the causes of the increased incidence of unprotected sex and substance use. The results of such research can be used to strengthen the health and wellbeing of communities of MSM around the world.

Click here to read the full publication (restricted access)

Keep up-to-date with drug policy developments by subscribing to the IDPC Monthly Alert.